Document is current
Any future updates will be listed below
-
Authors
Özcan, Demet
Nielsen, Patricia Switten
Alsner, Jan
Nielsen, Mette Holck
Maae, Else
Milo, Marie Louise Holm
Overgaard, Jens
Offersen, Birgitte Vrou
Tramm, Trine
-
Funding
Funding for this research was provided by:
Dansk Kræftforsknings Fond
Agnes og Poul Friis Fond
Kræftens Bekæmpelse (RR269-A15563)
Kræftens Bekæmpelse (R148-A10067-16-S46)
- License Information
-
More Information
Article History
Received: 24 December 2025
Accepted: 10 March 2026
First Online: 13 March 2026
Declarations
:
: The study was approved by The Central Denmark Region Committees on Health Research Ethics (journal no. 1-10-72-286-21), The Danish Data Protection Agency (journal no. 2022-522-0408), and registered in the Central Denmark Region’s internal list of research projects (case no. 1-16-02-323-21). The reporting follows Recommendation for Tumor Marker Prognostic Studies criteria [ ], and was conducted in accordance with the Declaration of Helsinki. Written informed consent was obtained from all participants prior to inclusion in the original randomized DBCG HYPO trial.
: Not applicable.
: Trine Tramm reports a relationship with AstraZeneca that includes: speaking and lecture fees. All other authors declare no competing interests.
